These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 20008750)

  • 21. Recent progress in hormonal therapy for advanced prostate cancer.
    Daskivich TJ; Oh WK
    Curr Opin Urol; 2006 May; 16(3):173-8. PubMed ID: 16679855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fracture risk in androgen deprivation therapy: a Canadian population based analysis.
    Lau YK; Lee E; Prior HJ; Lix LM; Metge CJ; Leslie WD
    Can J Urol; 2009 Dec; 16(6):4908-14. PubMed ID: 20003666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
    Grossmann M; Zajac JD
    Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.
    Spanjol J; Maricić A; Valencić M; Oguić R; Krpina K; Protić A; Ivancić A; Bobinac M; Fuckar D; Vojniković B
    Coll Antropol; 2008 Oct; 32 Suppl 2():79-81. PubMed ID: 19138011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy.
    Herr HW; O'Sullivan M
    J Urol; 2000 Jun; 163(6):1743-6. PubMed ID: 10799173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden.
    Thorstenson A; Bratt O; Akre O; Hellborg H; Holmberg L; Lambe M; Bill-Axelson A; Stattin P; Adolfsson J
    Eur J Cancer; 2012 Jul; 48(11):1672-81. PubMed ID: 22386317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and risk factors for low trauma fractures in men with prostate cancer.
    Ahlborg HG; Nguyen ND; Center JR; Eisman JA; Nguyen TV
    Bone; 2008 Sep; 43(3):556-60. PubMed ID: 18585119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intermittent androgen deprivation: clinical experience and practical applications.
    Wright JL; Higano CS; Lin DW
    Urol Clin North Am; 2006 May; 33(2):167-79, vi. PubMed ID: 16631455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fracture risk in Danish men with prostate cancer: a nationwide register study.
    Abrahamsen B; Nielsen MF; Eskildsen P; Andersen JT; Walter S; Brixen K
    BJU Int; 2007 Oct; 100(4):749-54. PubMed ID: 17822455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
    Takizawa I; Hara N; Nishiyama T; Isahaya E; Hoshii T; Takahashi K
    J Urol; 2010 Nov; 184(5):1971-6. PubMed ID: 20884032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic complications of androgen deprivation therapy for prostate cancer.
    Saylor PJ; Smith MR
    J Urol; 2013 Jan; 189(1 Suppl):S34-42; discussion S43-4. PubMed ID: 23234628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary intermittent androgen deprivation as initial therapy for men with newly diagnosed prostate cancer.
    Scholz MC; Lam RY; Strum SB; Labarba DJ; Becker LK; Chang P; Farhoumand N; Jennrich RI
    Clin Genitourin Cancer; 2011 Dec; 9(2):89-94. PubMed ID: 21993252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
    Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
    Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ACP Journal Club. Testosterone increased risk for adverse events in older men with mobility limitations.
    Lichtenstein MJ
    Ann Intern Med; 2010 Dec; 153(12):JC6-7. PubMed ID: 21173408
    [No Abstract]   [Full Text] [Related]  

  • 37. Improvement in prostate cancer survival over time: a 20-year analysis.
    Kim MM; Hoffman KE; Levy LB; Frank SJ; Pugh TJ; Choi S; Nguyen QN; McGuire SE; Lee AK; Kuban DA
    Cancer J; 2012; 18(1):1-8. PubMed ID: 22290249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ACP Journal Club: Use of antipsychotic drugs was associated with increased risk for hyperglycemia in older patients with diabetes.
    Ng B
    Ann Intern Med; 2009 Nov; 151(10):JC512. PubMed ID: 19920257
    [No Abstract]   [Full Text] [Related]  

  • 39. ACP Journal Club. Rosiglitazone was noninferior to metformin plus sulfonylurea for CV events but increased risk for HF and fractures in type 2 diabetes.
    Lipscombe LL
    Ann Intern Med; 2009 Oct; 151(8):JC4-8. PubMed ID: 19841445
    [No Abstract]   [Full Text] [Related]  

  • 40. ACP Journal Club: a single, annual, high dose of oral vitamin D increased falls and fractures in older women.
    Sanders K
    Ann Intern Med; 2010 Sep; 153(6):JC3-3. PubMed ID: 20855792
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.